Management of heparin in COVID-19 patients during the first phase of pandemic

Abstract

The coronavirus disease (COVID-19) is associated with a significant risk of thrombotic complications. We reported our first wave experience regarding the use of Low Molecular Weight Heparin (LMWH) and Fondaparinux in Covid-19 patients admitted to our Hospital. The aim of our study was to evaluate the effectiveness and safety of increased LWMH prophylaxis. 57 patients admitted to our hospital for COVID-19, median age 65, were studied from March to May 2020. We observed one thrombotic event and 3 bleedings. The incidence of thrombosis was 1.7%: this result is much lower than that reported by other studies regarding patients untreated with heparin or in prophylaxis at standard dosages. LMWH therapy has proven effective and safe in terms of thrombosis prevention and has contributed to the favourable outcome of hospitalizations.